Bisphosphonates for the preservation of periprosthetic bone mineral density after total joint arthroplasty: a meta-analysis of 25 randomized controlled trials

Original Article
  • 29 Downloads

Abstract

Summary

The present meta-analysis aimed to evaluate the long-term efficacy of bisphosphonates (BPs) on preservation of periprosthetic bone mineral density (BMD) after joint arthroplasty. It confirmed the protective effect of BPs in a long-term follow-up, and found the influence factors on this effect.

Introduction

Periprosthetic bone loss is believed to cause aseptic loosening and failed prosthetic fixation in joint arthroplasty. This meta-analysis which included high-quality randomized controlled trials aimed to analyze the effect of bisphosphonates on maintaining periprosthetic bone mineral density after total joint arthroplasty.

Methods

Twenty-five RCTs were included and the total number of participants was 1163 by computerized searches of bibliographic databases. The weighted mean differences with 95% confidence interval were calculated to evaluate the efficacy of BPs on total periprosthetic BMD and the BMD of different Gruen zones. Subgroup analyses identified the potentially influencing factors such as surgical site, cement fixation, and generation of BPs. A descriptive review was conducted for BP-related adverse effects.

Results

The BPs group presented significantly higher total periprosthetic BMD in the BPs group than that in the control group at 3, 6, 12 months, 2–4 years, and 5–10 years after arthroplasty (P < 0.05). The BPs group presented significantly higher periprosthetic BMD in femoral Gruen Zone 1 and 7 than that in the control group at 3, 6, 12 months, 2–4 years, and 5–10 years (P < 0.05). The heterogeneity was minimized by dividing THA and TKA into two subgroups. Subgroup analyses revealed that the effect of BPs on preservation of BMD was significantly greater in arthroplasty with cemented component than in that with uncemented component at 12 months and 5–10 years (P < 0.05), and the administration of the second and third generation BPs was significantly more effective than the first-generation BPs at 6 and 12 months (P < 0.05). None of the included studies described severe or fatal adverse effects related to BPs.

Conclusions

BPs have significantly long-term efficacy on the preservation of periprosthetic BMD after joint arthroplasty. To obtain a better efficacy, the cemented components and the second and third generation BPs are recommended.

Keywords

Arthroplasty Bisphosphonates Bone mineral density Meta-analysis 

Notes

Compliance with ethical standards

Conflicts of interest

None.

Supplementary material

198_2018_4488_Fig3_ESM.gif (111 kb)
ESM 1

The seven regions of interest based on Gruen zones. (GIF 111 kb)

198_2018_4488_MOESM1_ESM.tif (156 kb)
High Resolution (TIFF 156 kb)
198_2018_4488_MOESM2_ESM.docx (16 kb)
ESM 2 Characteristics of 19 excluded trials. (DOCX 16 kb)
198_2018_4488_Fig4_ESM.gif (1 kb)
ESM 3

The funnel plots asymmetry for the outcome showed the evidence of publication bias at 3 months (a), 6 months (b), 12 months (c), 2 to 4 years (d) and 5–10 years (e) after the arthroplasty. (GIF 971 bytes)

198_2018_4488_MOESM3_ESM.tif (1 mb)
High Resolution (TIFF 1045 kb)
198_2018_4488_MOESM4_ESM.doc (189 kb)
ESM 4 GRADE evidence profile of RCTs for effect of BPs on periprosthetic bone loss after joint arthroplasty. (DOC 189 kb)

References

  1. 1.
    Maradit Kremers H, Larson DR, Crowson CS, Kremers WK, Washington RE, Steiner CA, Jiranek WA, Berry DJ (2015) Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am 97(17):1386–1397CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kurtz S, Ong K, Lau E, Mowat F, Halpern M (2007) Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89(4):780–785PubMedGoogle Scholar
  3. 3.
    Brodner W, Bitzan P, Lomoschitz F, Krepler P, Jankovsky R, Lehr S, Kainberger F, Gottsauner-Wolf F (2004) Changes in bone mineral density in the proximal femur after cementless total hip arthroplasty. A five-year longitudinal study. J Bone Joint Surg Br 86(1):20–26CrossRefPubMedGoogle Scholar
  4. 4.
    Iwamoto N, Inaba Y, Kobayashi N, Ishida T, Yukizawa Y, Saito T (2011) A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty. J Bone Joint Surg Am 93(13):1203–1209CrossRefPubMedGoogle Scholar
  5. 5.
    Cherian JJ, Jauregui JJ, Banerjee S, Pierce T, Mont MA (2015) What host factors affect aseptic loosening after THA and TKA? Clin Orthop Relat Res 473(8):2700–2709CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fu SH, Wang CY, Yang RS, Wu FL, Hsiao FY (2017) Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan. J Bone Joint Surg Am 99(11):938–946CrossRefPubMedGoogle Scholar
  7. 7.
    Khatod M, Inacio MC, Dell RM, Bini SA, Paxton EW, Namba RS (2015) Association of bisphosphonate use and risk of revision after THA: outcomes from a US total joint replacement registry. Clin Orthop Relat Res 473(11):3412–3420CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lin T, Yan SG, Cai XZ, Ying ZM (2012) Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials. Osteoporos Int 23(6):1823–1834CrossRefPubMedGoogle Scholar
  9. 9.
    Gruen TA, McNeice GM, Amstutz HC (1979) “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res 141:17–27Google Scholar
  10. 10.
    Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mingmin Shi (2017). Effect of bisphosphonates on periprosthetic bone loss after total hip/knee arthroplasty. PROSPERO International prospective register of systematic reviews web. http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018085326. Acce3Assed 28 Jan 2018
  12. 12.
    Venesmaa PK, Kröger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM (2001) Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res 16(11):2126–2131CrossRefPubMedGoogle Scholar
  13. 13.
    Hennigs T, Arabmotlagh M, Schwarz A, Zichner L (2002) Dose-dependent prevention of early periprosthetic bone loss by alendronate. Z Orthop Ihre Grenzgeb 140(1):42–47CrossRefPubMedGoogle Scholar
  14. 14.
    Soininvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM, Kröger PJ (2002) Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int 71(6):472–477CrossRefPubMedGoogle Scholar
  15. 15.
    Nehme A, Maalouf G, Tricoire JL, Giordano G, Chiron P, Puget J (2003) Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study. Rev Chir Orthop Reparatrice Appar Mot 89(7):593–598PubMedGoogle Scholar
  16. 16.
    Yamaguchi K, Masuhara K, Yamasaki S, Fuji T, Seino Y (2004) Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty. Bone 35(1):217–223CrossRefPubMedGoogle Scholar
  17. 17.
    Wang YM, Li X, Wang JQ, Guo SY (2005) Study on the periprosthetic bone loss after cemented primary total hip replacement. Tianjin Med J 33:492–494Google Scholar
  18. 18.
    Arabmotlagh M, Rittmeister M, Hennigs T (2006) Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res 24(7):1336–1341CrossRefPubMedGoogle Scholar
  19. 19.
    Fokter SK, Komadina R, Repse-Fokter A (2006) Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. Wien Klin Wochenschr 118(Suppl 2):23–28CrossRefPubMedGoogle Scholar
  20. 20.
    Shetty N, Hamer AJ, Stockley I, Eastell R, Willkinson JM (2006) Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension. J Bone Joint Surg Br 88(10):1309–1315CrossRefPubMedGoogle Scholar
  21. 21.
    Wang CJ, Wang JW, Ko JY, Weng LH, Huang CC (2006) Three-year changes in bone mineral density around the knee after a six-month course of oral alendronate following total knee arthroplasty. A prospective, randomized study. J Bone Joint Surg Am 88(2):267–272CrossRefPubMedGoogle Scholar
  22. 22.
    Huang JF, Liu JB (2007) Alendronate prevents early femoral periprosthetic bone loss following total hip arthroplasty. J Jiangsu Univ (Medicine Edition) 17:542–544Google Scholar
  23. 23.
    Nishioka T, Yagi S, Mitsuhashi T, Miyamoto M, Tamura T, Kobayashi T, Enishi T (2007) Alendronate inhibits periprosthetic bone loss around uncemented femoral components. J Bone Miner Metab 25(3):179–183CrossRefPubMedGoogle Scholar
  24. 24.
    Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y (2007) Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int 18(7):1009–1015CrossRefPubMedGoogle Scholar
  25. 25.
    Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M (2009) Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res 27(2):183–188CrossRefPubMedGoogle Scholar
  26. 26.
    Tapaninen TS, Venesmaa PK, Jurvelin JS, Miettinen HJ, Kröger HP (2010) Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty—a 5-year follow-up of 16 patients. Scand J Surg 99(1):32–37CrossRefPubMedGoogle Scholar
  27. 27.
    Trevisan C, Ortolani S, Romano P, Isaia G, Agnese L, Dallari D, Grappiolo G, Cherubini R, Massari L, Bianchi G (2010) Decreased periprosthetic bone loss in patients treated with clodronate: a 1-year randomized controlled study. Calcif Tissue Int 86(6):436–446CrossRefPubMedGoogle Scholar
  28. 28.
    Sköldenberg OG, Salemyr MO, Bodén HS, Ahl TE, Adolphson PY (2011) The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am 93(20):1857–1864CrossRefPubMedGoogle Scholar
  29. 29.
    Iwamoto N, Inaba Y, Kobayashi N, Yukizawa Y, Ike H, Ishida T, Saito T (2014) The effectiveness of mono or combined osteoporosis drug therapy against bone mineral density loss around femoral implants after total hip arthroplasty. J Bone Miner Metab 32(5):539–544CrossRefPubMedGoogle Scholar
  30. 30.
    Scott DF, Woltz JN, Smith RR (2013) Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial. J Arthroplasty 28(4):671–675CrossRefPubMedGoogle Scholar
  31. 31.
    Zeng JC, Zeng YR, Fan YG, Yin CZ, Li J, Li FL, Chen K (2014) The preliminary clinical study of Aclasta in preventing bone loss at the early stage after total hip arthroplasty. Chin J Osteoporos 20(07):795–799Google Scholar
  32. 32.
    Jaroma AV, Soininvaara TA, Kröger H (2015) Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients. Bone Joint J 97-B(3):337–345CrossRefPubMedGoogle Scholar
  33. 33.
    Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T (2016) Teriparatide versus alendronate for the preservation of bone mineral density after total hip arthroplasty—a randomized controlled trial. J Arthroplast 31(1):333–338CrossRefGoogle Scholar
  34. 34.
    Muren O, Akbarian E, Salemyr M, Bodén H, Eisler T, Stark A, Sköldenberg O (2015) No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial. Acta Orthop 86(5):569–574CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Huang TW, Wang CJ, Shih HN, Chang Y, Huang KC, Peng KT, Lee MS (2017) Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial. BMC Musculoskelet Disord 18(1):209CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Yukizawa Y, Inaba Y, Kobayashi N, Choe H, Kubota S, Saito T (2017) Efficacy of alendronate for the prevention of bone loss in calcar region following total hip arthroplasty. J Arthroplast 32(7):2176–2180CrossRefGoogle Scholar
  37. 37.
    Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions. Chichester, England, Wiley-BlackwellCrossRefGoogle Scholar
  38. 38.
    Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009; 34:1929–1941Google Scholar
  39. 39.
    Shi MM, Cai XZ, Lin T, Wang W, Yan SG (2012) Is there really no benefit of vertebroplasty for osteoporotic vertebral fractures? A meta-analysis. Clin Orthop Relat Res 470(10):2785–2799CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490CrossRefPubMedGoogle Scholar
  41. 41.
    Catterall JB, Cawston TE (2003) Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther 5(1):12–24CrossRefPubMedGoogle Scholar
  42. 42.
    Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 40(4):275–284 e1–2CrossRefPubMedGoogle Scholar
  43. 43.
    Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Kiran A, de Vries F, Cooper C, Arden NK (2011) Fracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate use. Arthritis Rheum 63(4):992–1001CrossRefPubMedGoogle Scholar
  44. 44.
    Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P, de Vries F (2014) Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis Rheumatol 66(11):3233–3240CrossRefPubMedGoogle Scholar
  45. 45.
    Teng S, Yi C, Krettek C, Jagodzinski M (2015) Bisphosphonate use and risk of implant revision after total hip/knee arthroplasty: a meta-analysis of observational studies. PLoS One 10(10):e0139927CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Department of Orthopaedic Surgery, Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China
  2. 2.Department of Endocrinology and Metabolism, Sir Run Run Shaw Hospital Affiliated with School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations